Insulin Glargine in Type 2 Diabetic Patients

Summary

Primary: * To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c \< 7%) Secondary: * To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic, non-symptomatic and nocturnal hypoglycaemia) * To investigate whether beta cell function is preserved if this therapy is initiated before 2nd OAD (oral anti-diabetic drug) failure

Timeline

Start

2006-06

Primary completion

2008-05

Completion

—

Drugs

Indications